Opus Genetics, Inc.
IRD · XNASCIK 1228627fmd_05EMM5HZNXA2J4TE41X50SNFNMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2001 to Sep 30, 2026, 75 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 3 | 0 | 1 | 40 | 19 | 11 | 14 |
| Cost of revenue | – | – | – | – | – | – | – | – | – | – |
| Gross profit | – | – | – | – | – | – | – | – | – | – |
| Research and development | 10 | 11 | 13 | 2 | 7 | 15 | 14 | 18 | 27 | 31 |
| Total operating expenses | 16 | 17 | 21 | 4 | 20 | 23 | 22 | 30 | 73 | 53 |
| Operating income | (16) | (17) | (21) | (4) | (20) | (23) | 18 | (11) | (62) | (39) |
| Interest expense | – | – | – | 1 | 7 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
| Other non-operating income (expense) | 7 | (8) | 6 | (0) | 0 | (0) | (0) | 2 | 4 | 2 |
| Income before taxes | – | – | – | (6) | (25) | (57) | 18 | (10) | (58) | (50) |
| Income tax expense | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | (6) | (25) | (57) | 18 | (10) | (58) | (50) |
| Net income | (9) | (25) | (14) | (6) | (25) | (57) | 18 | (10) | (58) | (50) |